Evercore ISI Group maintains Inspire Medical Systems at In-Line, lowers price target to $60 from $72

Evercore ISI Group maintained its In-Line rating for Inspire Medical Systems but reduced its price target to $60 from $72. This implies a 10.7% downside from the Nov 2 close of $67.21. Recent analyst price targets for the company range from $62 to $78.

Original reporting
Published Nov 3, 2026, 3:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 3:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Evercore ISI Group maintains Inspire Medical Systems at In-Line, lowers price target to $60 from $72 — source image
Decision brief

The 30-second read

$INSPBearishLow
01

Why it matters

The target reduction signals a bearish view, likely prompting short‑term sell pressure.

02

Market read

Analyst target cut may influence INSP's price action and sentiment in the medical‑device sector.

03

What to watch

Potential pipeline developments not reflected in the target change.

Relevance 5/10Novelty 4/10Timing: today

Background

Evercore ISI provides analyst coverage for Inspire Medical Systems, a Nasdaq‑listed medical device company.

Company-level read

Ticker impact

$INSPBearishMedium confidence
Context

Evercore ISI lowered its price target for Inspire Medical Systems to $60 from $72.

Expected impact

likely pressure as investors price in the lower target

Evidence & confidence

Target cut implies downside of ~10% from recent close, prompting sell pressure.

Market effects

May weigh on other sleep‑apnea device makers.

Limited to US biotech/medical device sector.

Minimal global impact.

Counterpoint

Target cut could be over‑reactive; upside if upcoming trial data beats expectations.

Key entities

  • Inspire Medical Systems

    Developer of sleep‑apnea therapy devices, ticker INSP.

  • Evercore ISI Group

    Equity research firm that issued the price‑target downgrade.

Related articles

$INSPMedAI 8/10

Inspire (INSP) Q3 2026 Earnings Call Transcript

Inspire (INSP) reported Q3 2026 revenue of $206.7M, down 7.9% YoY but up 3% sequentially. The company expects stable coding framework in 2027 and a new code in 2028, with strong adoption of Inspire V. Operating loss was $28.7M, and adjusted EPS was $0.14. The company is investing in patient flow optimization and expanding market reach. According to the company, they remain confident in their path to growth.

$INSPMed

Inspire: Q3 Earnings Snapshot

Inspire Medical Systems (INSP) reported a Q3 loss of $24.4M, or 84 cents per share, but adjusted earnings of 14 cents per share, beating estimates. Revenue was $206.7M, also topping forecasts. The company expects full-year earnings of $1.20-$1.40 per share and revenue of $850M-$860M.

$INSPMed

Inspire Medical Systems Q3 Earnings Call Highlights

Inspire Medical Systems (INSP) reported Q3 earnings, estimating coding and reimbursement challenges reduced results by $30M and may impact 2026 results by $120M. The company expects revenue growth in Q4 and low-single-digit growth in 2027, citing stable coding and investments. Inspire highlighted a new CPT code for its Inspire V device and ongoing development of Inspire VI. Management discussed clinical evidence supporting their therapy and plans to invest in patient access and education.

$INSPHighAI 8/10

Inspire Medical Q3 2026 slides: reimbursement clarity ahead, growth reset

Inspire Medical Systems reported Q3 2026 revenue of $206.7M, down 7.9% YoY but up 3.0% sequentially. The company cited reimbursement challenges as the primary headwind. Shares rose 1.83% in after-hours trading. Inspire highlighted its market position and long-term growth potential, despite near-term slowdowns. The company expects full-year 2026 revenue of $850M-$860M, down from 2025 levels.